Changing Methods for Discovering Antiviral Drugs

  • Philip S. Jones
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 24)


Viral diseases were largely untreatable 40 yr ago. Now effective and safe therapies are available. This has led to significant improvements in the quality of life for large numbers of patients. New viral diseases are, however, continuing to emerge and established viruses have been shown to develop resistance to available therapies making this a fertile area for continued drug discovery. The processes used to discover drugs have also changed enormously over the past 40 yr. Nowhere have these changes been more apparent than in the field of antiviral therapy. Therefore, the development of antiviral drugs makes an excellent example for documenting the changes in approaches used to discover active agents. This brief chapter describes some of these changes—from the broad screening in animals and tissue culture first used to the mechanism-based approaches using computer assisted techniques and biostructural information.


Antiviral Therapy Antiviral Drug Neuraminidase Inhibitor Aspartyl Proteinase Viral Enzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sneader, W. (1985) The human herpesviruses, in Drug Discovery: The Evolution of Modern Medicines, Wiley, New York, p. 292.Google Scholar
  2. 2.
    Pinto, H., Holsinger, L. J., and Lamb, R. A. (1992) Influenza virus M2 protein has ion channel activity. Cell 69, 517–528.CrossRefPubMedGoogle Scholar
  3. 3.
    Sneader, W. (1985) Drug Discovery: The Evolution of Modern Medicines, Wiley, New York, p. 351.Google Scholar
  4. 4.
    Levine, A. J. (1992) Viruses, Scientific American Library, p. 74.Google Scholar
  5. 5.
    Harper, D. R. (1994) Medical applications—antiviral drugs, in Molecular Virology, Bios Scientific Publishers, pp. 93–110.Google Scholar
  6. 6.
    Pattishall, K. A. (1993) Discovery and development of zidovidine as the cornerstone of therapy to control human immunodeficiency virus infection, in The Search for Antiviral Drugs, Birkhauser, pp. 23–44.Google Scholar
  7. 7.
    Pauwels, R. (1993) Discovery of TIBO, a new family of HIV-1-specific reverse transcriptase inhibitors, in The Search for Antiviral Drugs, Birkhauser, Germany. pp. 71–104.Google Scholar
  8. 8.
    Adams, J. and Merluzzi, V. J. (1993) Discovery of Nevinipine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, in The Search for Antiviral Drugs, Birkhauser, pp. 45–70.Google Scholar
  9. 9.
    Romero, D. L. (1994) Ann. Rep. Med. Chem. 26, 123–132.CrossRefGoogle Scholar
  10. 10.
    Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 angstroms resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783–1790.CrossRefPubMedGoogle Scholar
  11. 11.
    Tong, L., Cardozo, M., Jones, P.-J., and Adams, J. (1993) Preliminary structural analysis of the mutations selected by non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biorg. Med. Chem. Lett. 3, 721–726.CrossRefGoogle Scholar
  12. 12.
    Jingshan, R., et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2, 293–302.CrossRefGoogle Scholar
  13. 13.
    Roberts, N. A., et al. (1990) Rational design of peptide based HIV proteinase inhibitors. Science 248, 358–361.CrossRefPubMedGoogle Scholar
  14. 14.
    Navia, M. A., Sato, V. L., and Tung, R. D. (1995) Design of VX-478, a potent inhibitor of HIV protease. Int. Antiviral News 3, 143–145.Google Scholar
  15. 15.
    Boehme, R. E., and Borthwick, A. D., and Wyatt, P. G. (1995) Antiviral agents. Ann. Rep. Med. Chem. 30, 144.Google Scholar
  16. 16.
    Ridky, T. and Leis, J. (1995) Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29,621–29,623.CrossRefPubMedGoogle Scholar
  17. 17.
    von Itzstein, M., et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418–423.CrossRefGoogle Scholar
  18. 18.
    Andries, K. (1993) Discovery of piroclavir, a broad spectrum inhibitor of ethnoviruses, in The Search for Antiviral Drugs, Birkhauser, Germany, pp. 179–210.Google Scholar
  19. 19.
    Liuzzi, M., et al. (1994) A potent inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695–698.CrossRefPubMedGoogle Scholar
  20. 20.
    Szymkowski, D. E. (1996) Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today 1, 415–428.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Philip S. Jones
    • 1
  1. 1.Roche Research CentreWelwyn Garden CityUK

Personalised recommendations